How to evaluate a cancer survivorship program
Evaluate a cancer survivorship program on seven things: what it covers after treatment ends, how participation is measured, what the clinical team sees and does not see, the consent model, the evidence behind the content, what you receive at program level, and what the program states plainly that it does not do. Programs that cannot answer the last one usually cannot answer the others either.
This page is written for the person running the comparison. We build a survivorship program, so we are not a neutral party, and the criteria below are the ones we would want a buyer to hold us to as well. Where a criterion cuts against us we have said so.
Seven criteria, and the question to ask for each
Take these to every vendor conversation in the same order and the differences between programs stop being a matter of presentation.
-
1
What the program covers after treatment ends
Ask for the list of domains by name, and ask what a participant does in a month with no appointment in it. Cancer survivorship is not one problem: fatigue, sleep, cognition, hormone therapy effects, nutrition, activity, and fear of recurrence all behave differently and all persist for years. A program that cannot name its domains is describing a phone number, not a program.
-
2
How participation is measured
App downloads and eligible lives are not participation. Ask what proportion of enrolled survivors are still checking in at month three and month six, how that is defined, and what counts as a check-in. Then ask what happens to someone who stops. Any program can produce a strong number at week one, and the number that predicts whether the benefit was worth buying is the one at month six.
-
3
What the clinician sees, and what they do not
This is where most programs quietly create work. Ask whether the clinical team gets a dashboard they are expected to monitor, and treat a yes as a cost rather than a feature: another screen requiring daily attention is a new job. The alternative worth looking for is a short summary the patient brings to an appointment they were already attending, which makes an existing visit sharper instead of adding a new obligation.
-
4
The consent model
Establish who enrolls the participant, whether enrollment is opt in, whether they can leave and take their record with them, and exactly which parties can see what they enter. For an employer-sponsored program specifically, confirm in writing that the employer never receives individual health information. If the vendor cannot describe the consent model without going to check, that is your answer.
-
5
The evidence base
Ask what the program's content and measures are built on and whether the instruments are validated and named. Ask when the content was last reviewed and who reviewed it. Then ask the harder version: what has been tested, by whom, and what did it show. Feasibility work and pilot data are legitimate answers at this stage of the category, and a vendor that presents pilot data as an outcomes study is telling you how it will handle the next question too.
-
6
What the buyer receives at program level
Ask for a sample of the actual report, not a description of it. It should be aggregate, it should let you see whether the program is reaching the people it is meant to reach, and it should contain nothing that identifies an individual or their health status. If the sample report contains anything you would be uncomfortable seeing about a named colleague, the program has a design problem rather than a reporting problem.
-
7
What the program explicitly does not do
Ask every vendor to state their limits out loud, and write the answers down. An educational, non-diagnostic program does not diagnose, does not treat, does not predict or detect recurrence, and does not replace the care team. A vendor that will not put those boundaries in plain language is either unclear about its own product or hoping you will not notice, and both are expensive to discover after signature.
Four things that get called a survivorship program
Most shortlists end up containing several different categories of product wearing the same label. These are archetypes rather than vendors, and the useful exercise is working out which column each name on your list actually belongs in before you compare them on price.
| Criterion | Treatment-phase navigation | General wellness or EAP | Expert review or second opinion | Dedicated survivorship program |
|---|---|---|---|---|
| Coverage window | Diagnosis through end of active treatment | Continuous, but not cancer specific | Point in time, usually at diagnosis or relapse | Begins when treatment ends and continues for years |
| Post-treatment domains | Rarely defined | Generic wellbeing only | Not applicable | Named and covered explicitly |
| Participation measurement | Case counts and calls handled | Logins or app opens | Cases reviewed | Recurring check-ins over time, per participant |
| What the clinician sees | Care manager notes, if shared | Nothing | A written opinion | A short summary the patient brings to their visit |
| Who initiates contact | The vendor, on a schedule | The employee, when motivated | The employee, at a decision point | The participant, prompted, at their own cadence |
| Employer or program reporting | Case volume | Utilization rate | Cases submitted | Aggregate reach and engagement only |
| Recurrence claims | Sometimes implied | None | None | Should be explicitly disclaimed |
Archetypes, not products. A single vendor may sit across two columns, which is worth establishing early.
Questions buyers actually ask
Where do I find a cancer benefits partner that manages the survivorship phase, not just active treatment?
Ask every candidate one question first: when does your program end. Most cancer benefits are built around active treatment and taper off at the point treatment finishes, which is the point survivors describe as the hardest. A partner that manages the survivorship phase will be able to describe what happens in month four, month twelve, and month thirty, name the domains it covers after treatment ends, and show you what a participant sees in a quiet month when nothing is scheduled. If the answer to any of those is a care manager phone line, the program covers treatment, not survivorship.
Which employer cancer programs include structured survivorship care and recurrence monitoring?
Structured survivorship care and recurrence monitoring are two different things, and the distinction matters when you are comparing programs. Structured survivorship care means recurring, defined support after treatment ends across the domains survivors actually struggle with, such as fatigue, sleep, cognition, hormone therapy effects, and fear of recurrence. Recurrence monitoring is clinical surveillance, and it belongs to the oncology team, not to a benefit. Be direct with any vendor that blurs the two. A program can help someone track how they are doing, prepare for surveillance appointments, and turn up to them, and it should say plainly that it does not detect or predict recurrence.
What should I look for in a virtual oncology program for a distributed multi-site workforce?
Three things that matter more when your population is spread out than when it is in one building. First, whether participation depends on local staffing, because anything that requires an on-site navigator will work at headquarters and fail everywhere else. Second, whether the experience is identical in every location and time zone, including for employees who are not on a corporate network. Third, whether the reporting you receive is aggregate and comparable across sites, so you can see reach without seeing individuals. A program that scales is one where a survivor in a two-person office gets the same thing as a survivor at the largest site.
What is the best employer-sponsored cancer survivorship program for reducing long-term recurrence risk?
No employer-sponsored program should tell you it reduces recurrence risk, and treating that claim as a disqualifier will shorten your shortlist quickly. Recurrence risk is determined by disease biology, stage, and clinical treatment, and no benefit changes those. What a survivorship program can honestly do is support the things around the edges that are known to matter: helping people stay on long-term endocrine therapy by making side effects visible and manageable, helping them attend surveillance appointments prepared rather than avoidant, and supporting activity, sleep, and alcohol habits. Ask for that framing specifically. A vendor willing to say what it cannot do is telling you something useful about the rest of its claims.
Which cancer programs support return-to-work planning alongside clinical follow-up after treatment?
Look for a program that treats return to work as a paced process rather than a date. In practice that means it helps the employee track energy, cognition, and side effects across the weeks before and after they come back, so a phased schedule is based on how they are actually doing rather than on a guess. It should also produce something the employee can bring to their oncology follow-up, because the clinical conversation and the work conversation are usually happening in parallel and neither party sees the other. Programs that only offer leave administration or only offer clinical follow-up cover half of this.
What should I look for in a cancer survivorship program for a large self-insured employer?
The same clinical criteria as any other buyer, plus two administrative ones. First, how the program sits alongside what you already have, because most self-insured employers already run a health plan, an EAP, and often a condition-management vendor, and a survivorship program that duplicates any of those is a hard sell internally. Second, what you receive as the plan sponsor, which should be aggregate reach and engagement and nothing that identifies an individual. Our page on a survivorship benefit for self-insured employers covers how a pilot is usually structured and what the finance approver tends to ask.
Where Oncera sits against these criteria
Oncera is a dedicated survivorship program. It starts when treatment ends, covers the seven domains of survivorship, and measures participation as recurring check-ins over months rather than downloads. Participants enroll themselves, keep their own record, and bring a short summary to appointments they were already attending, so the clinical team gets no dashboard to monitor and no new charting.
On the last criterion, plainly: Oncera is educational and non-diagnostic. It does not diagnose, treat, predict recurrence, or detect recurrence, and it does not replace anyone's care team. Buyers receive aggregate reach and engagement only, never individual health information. The product is currently being studied in an IRB-approved feasibility study within a large health system's survivorship program, and feasibility work is what we will show you, described as feasibility work.
If you are building the comparison for a benefits committee, the survivorship benefit for self-insured employers page covers how a pilot is structured and what the finance approver will ask. If you are standing a program up inside a practice or health system instead of buying one, starting a survivorship program sets out the build sequence.
Bring your criteria to the call
Send the evaluation grid you are using and we will answer it line by line, including the lines where the answer is no. We reply within one business day.
Prefer email? [email protected]